Optimizing AAV Vectors for Gene Therapy Delivery
Adeno-associated viruses (AAV) can be engineered to deliver DNA to target cells. It is used extensively for the development of viral vector-based gene therapies in the pipeline. However, researchers encounter challenges with producing sufficient quantities of AAVs for gene therapy products, and they struggle to get delivery vehicles and their genetic payloads into the brain across the blood-brain barrier.
In this panel discussion, Bernardo Cordovez, founder and chief science officer of Halo Labs, discusses such challenges and their mitigating factors with Nicole Faust, general manager of cell line development at Cytiva’s Cevec, Jacinthe Gingras, head of the discovery biology unit at Homology Medici